Impact of the Procurement Technique on Outcomes After Liver Transplantation

NCT07582978 | Not Yet Recruiting

• 1 other identifier: APHP250871
• Study Type: observational
• Target: 1,810
• Locations: 0 countries
• Sites: N/A

Brief Summary

Liver transplantation (LT) is the standard treatment for hepatocellular carcinoma (HCC) and end-stage liver disease, with excellent long-term outcomes despite the increasing use of extended criteria donors due to organ shortage. As traditional evaluation criteria have become insufficient, new indicators such as Arterial and Biliary Complication-Free Survival (ABCFS) have been developed to better assess post-transplant outcomes. Primary objective: To assess, in a large-scale study, whether the procurement technique influences liver transplantation outcomes in terms of arterial and biliary complication-free survival.

Conditions

Liver Transplantation

Keywords

liver transplantation; LT; hepatocellular carcinoma (HCC); Arterial and Biliary Complication-Free Survival; procurement technique

Outcome Measures

Primary Outcomes (1)

• Arterial and Biliary Complication-Free Survival (ABCFS) at 3 years

  at 3 years post-transplantation

Secondary Outcomes (7)

• Postoperative complications at 90 days

  at 90 days post-transplantation

• Type of Biliary complications

  Up to 3 years post-transplantation

• Type of Arterial complications

  Up to 3 years post-transplantation

• Occurrence of vascular injuries observed following organ procurement

  Peri-procedural period (during procurement and immediately post-procurement)

• Rehospitalization Rate Post-LT

  Up to 3 years post-transplantation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

adult patients (≥18 years) who undergo a first liver transplantation in France.

You may qualify if:

• Listed on the national waiting list of the Agence de la Biomédecine (ABM)
• Undergoing a first liver transplantation in France
• Receiving a whole liver graft
• No prior or subsequent transplantation of another organ

You may not qualify if:

• Pancreas procurement
• Multiorgan transplantation
• Split liver transplantation (shared grafts)
• Retransplantation
• Domino transplantation (no actual organ procurement in the conventional sense)
• Patient refusal to allow the use of their data

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Officials

• Astrid HERRERO, MD, PhD

  Saint Eloi Hospital, Montpellier University Hospital

  STUDY CHAIR

Central Study Contacts

Eric Savier, MD, PhD

CONTACT

+33 1 42 17 56 90; eric.savier@aphp.fr

Jinmi BAEK

CONTACT

jinmi.baek@aphp.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 28, 2026
• First Posted: May 13, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 1, 2031
• Study Completion (Estimated): September 1, 2031
• Last Updated: May 13, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share